Study showed that insulin products are highly rebated and that the net prices for payers increased at a slower pace than list prices from 2012 to 2019.
In the face of rising healthcare costs, a recent study has shed light on the persistent issue of high insulin prices, despite the introduction of new discounts. This has significant implications for patients who rely on insulin for managing their diabetes.
- A study published in JAMA Health Forum in June 2023 found that insulin prices increased substantially from 2012 to 2015.
- The introduction of new insulin products to the market led to an increase in discounting practices, lowering the net price for payers.
- Despite these discounts, 25% of patients reported that cost impedes their access to necessary insulin.
According to the American Diabetes Association, more than 34 million Americans, or just over 1 in 10, have diabetes.
More on Type 2 Diabetes